WO2017179611A1 - 硫酸化多糖類を用いた免疫学的測定法 - Google Patents
硫酸化多糖類を用いた免疫学的測定法 Download PDFInfo
- Publication number
- WO2017179611A1 WO2017179611A1 PCT/JP2017/014943 JP2017014943W WO2017179611A1 WO 2017179611 A1 WO2017179611 A1 WO 2017179611A1 JP 2017014943 W JP2017014943 W JP 2017014943W WO 2017179611 A1 WO2017179611 A1 WO 2017179611A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- measured
- substance
- antibody
- sulfated polysaccharide
- sample
- Prior art date
Links
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 67
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 67
- 150000004676 glycans Chemical class 0.000 title claims abstract description 9
- 238000003018 immunoassay Methods 0.000 title description 9
- 239000000126 substance Substances 0.000 claims abstract description 65
- 238000000034 method Methods 0.000 claims abstract description 45
- 239000000523 sample Substances 0.000 claims abstract description 44
- 210000002966 serum Anatomy 0.000 claims abstract description 39
- 239000012472 biological sample Substances 0.000 claims abstract description 19
- 239000007853 buffer solution Substances 0.000 claims abstract description 12
- 239000000243 solution Substances 0.000 claims description 51
- 238000005259 measurement Methods 0.000 claims description 39
- 210000004369 blood Anatomy 0.000 claims description 21
- 239000008280 blood Substances 0.000 claims description 21
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims description 18
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims description 18
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims description 16
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 16
- 229920000669 heparin Polymers 0.000 claims description 13
- 229960002897 heparin Drugs 0.000 claims description 13
- 229960000633 dextran sulfate Drugs 0.000 claims description 12
- 229920000858 Cyclodextrin Polymers 0.000 claims description 11
- 239000006249 magnetic particle Substances 0.000 claims description 10
- 239000001116 FEMA 4028 Substances 0.000 claims description 9
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 9
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 9
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 9
- 229960004853 betadex Drugs 0.000 claims description 9
- 238000000926 separation method Methods 0.000 claims description 8
- 230000001900 immune effect Effects 0.000 claims description 7
- 239000013076 target substance Substances 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 5
- 230000027455 binding Effects 0.000 claims description 4
- 239000003146 anticoagulant agent Substances 0.000 claims description 3
- 229940127219 anticoagulant drug Drugs 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 abstract description 41
- 238000012360 testing method Methods 0.000 abstract description 23
- 230000002452 interceptive effect Effects 0.000 abstract description 6
- 230000023555 blood coagulation Effects 0.000 abstract description 4
- 239000003130 blood coagulation factor inhibitor Substances 0.000 abstract description 4
- 229940127121 immunoconjugate Drugs 0.000 abstract 1
- 150000004804 polysaccharides Chemical class 0.000 description 60
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 33
- 239000012898 sample dilution Substances 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 229920000126 latex Polymers 0.000 description 12
- 239000004816 latex Substances 0.000 description 12
- 230000009257 reactivity Effects 0.000 description 12
- 239000002245 particle Substances 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 9
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 238000002372 labelling Methods 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 102000004903 Troponin Human genes 0.000 description 6
- 108090001027 Troponin Proteins 0.000 description 6
- 238000000691 measurement method Methods 0.000 description 6
- -1 polyethylene Polymers 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- UKWLRLAKGMZXJC-QIECWBMSSA-L disodium;[4-chloro-3-[(3r,5s)-1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl]phenyl] phosphate Chemical compound [Na+].[Na+].O1OC2([C@@H]3CC4C[C@H]2CC(Cl)(C4)C3)C1(OC)C1=CC(OP([O-])([O-])=O)=CC=C1Cl UKWLRLAKGMZXJC-QIECWBMSSA-L 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000004020 luminiscence type Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 241000711549 Hepacivirus C Species 0.000 description 3
- 239000007993 MOPS buffer Substances 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960002086 dextran Drugs 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000016178 immune complex formation Effects 0.000 description 3
- 238000010324 immunological assay Methods 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 2
- GUQQBLRVXOUDTN-XOHPMCGNSA-N 3-[dimethyl-[3-[[(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]propyl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 GUQQBLRVXOUDTN-XOHPMCGNSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 241000589886 Treponema Species 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- NNCRHRDBFDCWPA-UHFFFAOYSA-N ethyl dimethyl ammonio propane sulfonate Chemical compound CC[N+](C)(C)CCCS([O-])(=O)=O NNCRHRDBFDCWPA-UHFFFAOYSA-N 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 238000003317 immunochromatography Methods 0.000 description 2
- JORABGDXCIBAFL-UHFFFAOYSA-M iodonitrotetrazolium chloride Chemical compound [Cl-].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C=CC=CC=2)=N1 JORABGDXCIBAFL-UHFFFAOYSA-M 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229940043138 pentosan polysulfate Drugs 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 1
- BCHIXGBGRHLSBE-UHFFFAOYSA-N (4-methyl-2-oxochromen-7-yl) dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C=CC2=C1OC(=O)C=C2C BCHIXGBGRHLSBE-UHFFFAOYSA-N 0.000 description 1
- KZKAYEGOIJEWQB-UHFFFAOYSA-N 1,3-dibromopropane;n,n,n',n'-tetramethylhexane-1,6-diamine Chemical compound BrCCCBr.CN(C)CCCCCCN(C)C KZKAYEGOIJEWQB-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- MEJASPJNLSQOAG-UHFFFAOYSA-N 3-[benzyl(dimethyl)azaniumyl]propane-1-sulfonate Chemical compound [O-]S(=O)(=O)CCC[N+](C)(C)CC1=CC=CC=C1 MEJASPJNLSQOAG-UHFFFAOYSA-N 0.000 description 1
- REEBJQTUIJTGAL-UHFFFAOYSA-N 3-pyridin-1-ium-1-ylpropane-1-sulfonate Chemical compound [O-]S(=O)(=O)CCC[N+]1=CC=CC=C1 REEBJQTUIJTGAL-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 241001316595 Acris Species 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 229910000531 Co alloy Inorganic materials 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 229920000855 Fucoidan Polymers 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- YEJCDKJIEMIWRQ-UHFFFAOYSA-N Linopirdine Chemical compound O=C1N(C=2C=CC=CC=2)C2=CC=CC=C2C1(CC=1C=CN=CC=1)CC1=CC=NC=C1 YEJCDKJIEMIWRQ-UHFFFAOYSA-N 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910000914 Mn alloy Inorganic materials 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 229910000990 Ni alloy Inorganic materials 0.000 description 1
- VUVRUZSNPDKMBV-UHFFFAOYSA-N P(=O)(O)(O)O.C1(=CC=CC=C1)[Na] Chemical compound P(=O)(O)(O)O.C1(=CC=CC=C1)[Na] VUVRUZSNPDKMBV-UHFFFAOYSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- QWXOJIDBSHLIFI-UHFFFAOYSA-N [3-(1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl)phenyl] dihydrogen phosphate Chemical compound O1OC2(C3CC4CC2CC(Cl)(C4)C3)C1(OC)C1=CC=CC(OP(O)(O)=O)=C1 QWXOJIDBSHLIFI-UHFFFAOYSA-N 0.000 description 1
- XYIPYISRNJUPBA-UHFFFAOYSA-N [3-(3'-methoxyspiro[adamantane-2,4'-dioxetane]-3'-yl)phenyl] dihydrogen phosphate Chemical compound O1OC2(C3CC4CC(C3)CC2C4)C1(OC)C1=CC=CC(OP(O)(O)=O)=C1 XYIPYISRNJUPBA-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229910001622 calcium bromide Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- WGEFECGEFUFIQW-UHFFFAOYSA-L calcium dibromide Chemical compound [Ca+2].[Br-].[Br-] WGEFECGEFUFIQW-UHFFFAOYSA-L 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- COWYTPMAAISPHT-SWSWVKNJSA-A chembl411368 Chemical compound [K+].[K+].[K+].[K+].[K+].[K+].[K+].[K+].[K+].[K+].[K+].[K+].[K+].[K+].O1C(COS([O-])(=O)=O)[C@@H]2C(O)C(OS([O-])(=O)=O)[C@@H]1O[C@H](C(COS([O-])(=O)=O)O1)C(O)C(OS([O-])(=O)=O)[C@H]1O[C@H](C(COS([O-])(=O)=O)O1)C(O)C(OS([O-])(=O)=O)[C@H]1O[C@H](C(COS([O-])(=O)=O)O1)C(O)C(OS([O-])(=O)=O)[C@H]1O[C@H](C(COS([O-])(=O)=O)O1)C(O)C(OS([O-])(=O)=O)[C@H]1O[C@H](C(COS([O-])(=O)=O)O1)C(O)C(OS([O-])(=O)=O)[C@H]1O[C@H](C(COS([O-])(=O)=O)O1)C(O)C(OS([O-])(=O)=O)[C@H]1O2 COWYTPMAAISPHT-SWSWVKNJSA-A 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229950007870 hexadimethrine bromide Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
- 229910001623 magnesium bromide Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- FSVCQIDHPKZJSO-UHFFFAOYSA-L nitro blue tetrazolium dichloride Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 FSVCQIDHPKZJSO-UHFFFAOYSA-L 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000012123 point-of-care testing Methods 0.000 description 1
- 229920002454 poly(glycidyl methacrylate) polymer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229910000859 α-Fe Inorganic materials 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
- G01N33/548—Carbohydrates, e.g. dextran
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
- G01N33/54333—Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/12—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar
- G01N2400/14—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar alpha-D-Glucans, i.e. having alpha 1,n (n=3,4,6) linkages between saccharide units, e.g. pullulan
- G01N2400/18—Cyclodextrin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/12—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar
- G01N2400/14—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar alpha-D-Glucans, i.e. having alpha 1,n (n=3,4,6) linkages between saccharide units, e.g. pullulan
- G01N2400/22—Dextran
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
- G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
Definitions
- the present invention relates to an immunoassay and a kit for suppressing measurement deviation between different test samples (particularly, between serum and heparinized plasma) using a sulfated polysaccharide.
- blood samples serum, plasma or whole blood
- serum is a biological sample unsuitable for methods for rapid assessment of cardiac troponin
- whole blood is known to make quantitative assays difficult to perform.
- immunoassays performed with heparinized plasma or heparinized whole blood often unreliable results are obtained even if the performance of the method used is very high.
- this problem is encountered when the concentration of cardiac muscle troponin in plasma is not very high (Non-patent Document 1).
- Non-patent Document 1 Non-patent Document 1
- the presence of heparin in blood samples can interfere during various immunological measurements and influence the measurement results, thereby modifying the physician's clinical diagnosis.
- Immunologically characterized in that it has been performed in the presence of hexadimethrine bromide (polybrene) on heparin-containing biological samples, with respect to a method for avoiding the influence of interfering substances in the sample in cardiac troponin assays to date.
- a measurement method is disclosed (Patent Document 2). However, it has not yet been sufficient to stably measure clinical samples.
- soluble interleukin 2 receptor hereinafter referred to as sIL-2R
- a biological sample serum and heparinized plasma
- the present invention relates to types of test samples, such as serum and heparinized plasma by using different blood coagulation inhibitors which are generally used when detecting a measurement target substance (for example, sIL-2R) in a biological sample. It is an object of the present invention to provide a measurement method and a kit capable of obtaining stable and highly accurate measurement values without being affected by interference substances in a test sample regardless of the above.
- the present inventors have determined sulfated polysaccharide in a reaction solution in a method for immunologically measuring sIL-2R in serum and heparinized plasma. To obtain a stable and accurate measurement value without being affected by interfering substances in a test sample regardless of the type of test sample by measuring the sIL-2R under the added conditions To complete the present invention.
- the present invention can be exemplified as follows. [1] In the method of immunologically measuring a substance to be measured in a biological sample, the formation of an immune complex of the substance to be measured and an antibody specifically binding to the substance to be measured is formed in the presence of a sulfated polysaccharide.
- a method for measuring the substance to be measured characterized in that [2] In the immunological measurement of a substance to be measured in a biological sample, the difference between the measured value when using a blood sample to which heparin is added as an anticoagulant and the measured value when using serum A method of reducing the formation of an immune complex of a substance to be measured and an antibody that specifically binds to the substance to be measured in the presence of a sulfated polysaccharide; [3] The method of [1] or [2], wherein the sulfated polysaccharide is dextran sulfate, ⁇ -cyclodextrin sulfate, [4] The method according to any one of [1] to [3], wherein the sulfated polysaccharide is contained in a specimen diluent and / or an antibody solution, [5] The method of any one of [1] to [4], which comprises the step of B / F separation of the formed immune complex.
- [6] The method according to any one of [1] to [5], wherein the first antibody and the second antibody that specifically bind to the substance to be measured are brought into contact, and the immune complex formed by the antigen-antibody reaction is measured.
- the substance to be measured is a soluble interleukin 2 receptor, a prostate specific antigen,
- a kit for measuring a substance to be measured which comprises an antibody that specifically binds to a substance to be measured, and a buffer solution containing a sulfated polysaccharide, for the method according to any one of [1] to [7].
- kits according to [8] which comprises, as the antibody, an antibody that specifically binds to the substance to be measured carried on magnetic particles.
- the kit of [8] or [9] wherein the substance to be measured is a soluble interleukin 2 receptor, a prostate specific antigen.
- the substance to be measured for example, sIL-2R
- the type of test sample serum and heparinized plasma
- stable and accurate measurement can be performed without being affected by interference substances in the test sample.
- the biological sample in the present invention is a sample that may contain the substance to be measured (eg, sIL-2R) collected from humans and the like.
- the biological sample include whole blood, blood samples such as serum and plasma, and in particular, it is preferable that the test sample contains serum and heparinized plasma.
- the test sample (specimen) usable in the present invention may be any measurement sample that can be prepared from the biological sample.
- a blood coagulation inhibitor is used.
- Samples such as whole blood, serum and plasma obtained by As the blood coagulation inhibitor, for example, heparin, EDTA, citric acid and the like can be used.
- these can be added to a blood collection tube etc. in advance and used.
- serum and heparinized plasma are targeted in parallel, the effect of the present invention is high, which is preferable.
- the substance to be measured in the present invention is not particularly limited as long as it can be measured by an immunoassay.
- examples include proteins, glycoproteins, lipid proteins, receptors, enzymes, viral antigens, antiviral antibodies, etc.
- soluble interleukin 2 receptor sIL-2R
- PSA prostate specific antigen
- HBV hepatitis C virus
- HCV hepatitis C virus
- HAV human immunodeficiency virus
- HTLV-1 human T cell leukemia virus-1
- TP syphilis treponema
- CKMB cardiac muscle markers
- myoglobin myoglobin, troponin
- various cardiac muscle markers various cardiac muscle markers (creatine kinase (CKMB), myoglobin, troponin), various hormones and the like.
- CKMB tine kinase
- the soluble interleukin 2 receptor is mainly present on the membrane of T cells that are immune cells, forms a complex with the ligand interleukin 2 and promotes the activation of T cell function, etc. Is a receptor involved in 2).
- the interleukin 2 receptor has three subtypes, and the ⁇ subunit in it is known to be isolated from cell membranes and present in blood. Soluble interleukin 2 receptor is considered to be involved in immune regulation in the body because it retains binding to interleukin 2 and is mainly used as a marker for acute leukemia in clinical practice.
- the immunological assay that can be used in the present invention may be any known method using an antibody specific to the substance to be measured.
- immunoturbidimetric assay TIA
- enzyme-linked immunosorbent assay EIA
- radioimmunoassay RIA
- latex agglutination fluorescent immunoassay
- immunochromatography etc.
- an immune complex is formed between a measurement target substance in a test sample and an antibody specific to the measurement target substance in a reaction solution, and a signal resulting from the formation is appropriately detected. It is a method of detecting the presence of the substance to be measured.
- the antibody to be used can be determined according to the measurement system, but in quantitative measurement with high sensitivity, a sandwich immunoassay (two or more immunoassays) using two or more antibodies can be selected. .
- the method of sandwich immunoassay may be performed in one or more steps (two steps, three steps, etc.). For example, forming an immune complex of a substance to be measured and an antibody that specifically binds to the substance to be measured supported on an insoluble carrier for B / F separation, B / F separation of the immunocomplex And a method comprising the step of measuring the separated immune complex.
- a sample prepared from the biological sample as described above is further prepared as a sample for measurement using a sample dilution liquid.
- An insoluble carrier carrying an antibody (first antibody) that specifically binds to sIL-2R, and an antibody that specifically binds to sIL-2R different from the first antibody labeled with a labeling substance (second) This is carried out by measuring the amount of the labeled substance bound to the insoluble carrier after mixing with the antibody to form an immune complex, and washing to remove unreacted antibody and sIL-2R (B / F separation). be able to.
- the material of the insoluble carrier includes, for example, latex, rubber, polyethylene, polypropylene, polystyrene, styrene-butadiene copolymer, polyvinyl chloride, polyvinyl acetate, polyacrylamide, polymethacrylate, styrene-methacrylate copolymer, polyglycidyl methacrylate Polymer materials such as acrolein-ethylene glycol dimethacrylate copolymer, polyvinylidene difluoride (PVDF) and silicone; agarose; gelatin; red blood cells; inorganic materials such as silica gel, glass, inert alumina, magnetic material etc. . One or more of these may be combined.
- VDF polyvinylidene difluoride
- examples of the form of the insoluble carrier include microtiter plates, test tubes, beads, particles, nanoparticles and the like.
- examples of the particles include magnetic particles, hydrophobic particles such as polystyrene latex, copolymerized latex particles having hydrophilic groups such as amino groups and carboxyl groups on the particle surface, red blood cells, gelatin particles and the like.
- magnetic particles are particularly preferable from the viewpoint of realizing quick and easy B / F separation, and specifically, for example, triiron tetraoxide (Fe 3 O 4 ), diiron trioxide (Fe 2 O 3 ), Magnetic particles such as fine particles made of various ferrites, metals such as iron, manganese, nickel, cobalt and chromium, and alloys of cobalt, nickel and manganese are preferably used.
- those magnetic particles can be preferably prepared in the form of being contained in the inside of a polymer latex such as polystyrene, gelatin, a liposome, etc., or those immobilized on the surface can be preferably used.
- the immobilization can be performed by, for example, a physical adsorption method, a covalent bonding method, an ionic bonding method, a combination thereof, or the like.
- the labeling substance is not particularly limited as long as it is a labeling substance that can be used in a conventional immunological measurement method, and examples include enzymes, fluorescent substances, radioactive isotopes, insoluble particulate substances and the like.
- the enzyme for labeling include alkaline phosphatase, peroxidase, glucose oxidase, tyrosinase, acid phosphatase and the like.
- fluorescent substances fluorescein isothiocyanate (FITC), green fluorescent protein (GFP), luciferin and the like can be mentioned.
- FITC fluorescein isothiocyanate
- GFP green fluorescent protein
- luciferin luciferin
- radioactive isotopes 125 I, 14 C, 32 P and the like can be mentioned.
- the labeling substance can be measured by performing a luminescence, fluorescence or color reaction using a substrate for the enzyme.
- the enzyme is alkaline phosphatase
- CDP-star registered trademark
- CSPD® 4-chloro-3- (methoxyspiro ⁇ 1,2-dioxetane-3,2 ′-(5′-chloro) tricyclo
- CSPD® 4-methoxyspiro ⁇ 1,2-dioxetane-3,2-) (5'-chloro) tricyclo [3.3.1.1 3,7 ] decane ⁇ -4-yl) phenylsodium disodium
- AMPPD registered trademark
- APS- A chemiluminescent substrate such as
- the antibody that specifically binds to sIL-2R is not particularly limited as long as it is a monoclonal antibody or polyclonal antibody that recognizes the amino acid sequence or steric structure of sIL-2R as an epitope, for example, antibody AM92 .3 (Pierce), monoclonal antibody 7G7 / B6 (Pierce), MAB 223 (R & D Systems), MAB 623 (R & D Systems), MAB 1020 (R & D Systems), YNRhIL2R (SANTA CRUZ BIOTECHNOLOGY) ), IL2R.
- These antibodies can be used to immunize animals, for example, in the case of sIL-2R, using sIL-2R purified from human T cells or recombinant sIL-2R prepared in vitro as the antigen.
- epitopes can be determined. Epitope means not only the minimum region recognized by an antibody but also one identified as a region recognizable by the antibody. Alternatively, they may be antibody fragments such as Fab that can be prepared by known methods. Also, these antibodies can be appropriately purchased from Genway Biotech, Diaclone, Santa Cruz, R & D Systems, etc.
- the measurement of the present invention it is possible to form an immune complex with a substance to be measured (for example, sIL-2R) in a biological sample, but it is not limited.
- a substance to be measured for example, sIL-2R
- the epitopes recognized by the first and second antibodies are different.
- monoclonal antibodies and polyclonal antibodies can be used in appropriate combination.
- the first antibody and the second antibody can be used in combination of two or more without being limited to one each.
- the addition of the sulfated polysaccharide in the present invention is carried out by the above-mentioned immunological assay, in which the substance to be measured (eg sIL-2R) and the antibody specifically binding to the substance to be measured (eg sIL-2R) It may be carried out so as to be present at least at the time of the first immunocomplex formation (in the reaction solution). Specifically, it may be added simultaneously at the time of immune complex formation (in the reaction solution), but it is added to the sample before complex formation (before the antibody and the analyte-containing sample come into contact). Also good.
- the substance to be measured eg sIL-2R
- the antibody specifically binding to the substance to be measured eg sIL-2R
- the sulfated polysaccharide to be added can be dissolved in a known buffer and prepared as a solution. In addition to the buffer, it may be prepared alone, or may be prepared together with known substances necessary for pretreatment of the sample or reaction. Since the sulfated polysaccharide may be added at least at the time of immune complex formation (in the reaction solution) as described above, it can be contained in a buffer which can be present at that time.
- the buffer solution etc. which can be made present at the time of immune complex formation can be appropriately set depending on the measurement method and apparatus used, but for example, the sample dilution solution, antibody solution (antibody solid phase particle solution, labeled antibody And the like. Also, it may be added to a plurality of buffers.
- sulfated polysaccharides in the present invention dextran sulfate, ⁇ -cyclodextrin sulfate, N-acetyl heparin (NAH), N-acetyl-de-O-sulfated-heparin (NA-de-o-SH), de- N-Sulfated-Heparin (De-NSH), De-N-Sulfated-Acetylated-Heparin (De-NSAH), Period-Acid Oxidized Heparin (POH), Chemically Sulfated Laminarin (CSL), Chemically These include sulfated alginic acid (CSAA), chemically sulfated pectin (CSP), heparin-derived oligosaccharide (HDO), pentosan polysulfate (PPS), fucoidan and the like.
- NAH N-acetyl heparin
- NA-NSH N-acetyl-de-O-s
- dextran sulfate and beta cyclodextrin sulfate are mentioned.
- the substance may be added in any form as long as it is supplied so as to be present as ions in the reaction solution, and examples thereof include a chlorinated sulfated polysaccharide and a hydrolyzed sulfated polysaccharide.
- sodium chloride is preferred.
- the concentration of the sulfated polysaccharide in the present invention is more than 0.0000004%, preferably 0.000004% or more, preferably 0.00004% or more, more preferably 0.0004%, as the concentration at the time of the formation of the immunocomplex. Or more, more preferably 0.004% or more, more preferably 0.04% or more, more preferably 0.01% or more, more preferably 0.02% or more, and 1% or less, preferably 0.4% Hereinafter, more preferably, it is selected in combination from 0.04% or less.
- the sulfated polysaccharide in the reaction solution is allowed to be present in the above concentration range It is. It should be noted that if the sulfated polysaccharide in the reaction solution is increased too much, the antigen-antibody reaction is suppressed (inhibited) and it becomes impossible to perform the target measurement accurately, so care must be taken.
- sulfated polysaccharide for example, heparin in heparinized plasma
- the amount of the substance to be measured (for example, sIL-2R) contained in the sample and the sulfate used
- determining the concentration to be added is a range of design.
- dextran sulfate molecular weight: 20,000
- dextran sulfate molecular weight: 4,000
- ⁇ -cyclodextrin sulfate is 0.
- 02% or more and 0.4% or less there may be mentioned 02% or more and 0.4% or less.
- the concentration and type of sulfated polysaccharide in the present invention are prepared by preparing a heparin-added blood sample (heparinized plasma) and other blood samples (serum), as shown in the following examples.
- a heparin-added blood sample heparinized plasma
- other blood samples serum
- the concentration and type of the sulfated polysaccharide in the present invention were measured values when using a blood sample (heparinized plasma) to which heparin was added as an anticoagulant, and other blood samples (serum). It is possible to select from a concentration range that matches the measured value of the case. Specifically, when the measured values are in agreement, the measured values (such as the optical count provided by the measuring instrument and the concentration calculated using the standard substance) fall within the range of -10% to + 10%. It means that. In general, if it is in between, it can be considered clinically useful.
- the kit of the present invention can be used to carry out the method of the present invention, and comprises an antibody that specifically binds to a substance to be measured (eg, sIL-2R) and a buffer containing a sulfated polysaccharide. .
- a substance to be measured eg, sIL-2R
- a buffer containing a sulfated polysaccharide eg, sIL-2R
- the antibody that specifically binds to the substance to be measured may be the known antibody described above, or may be either a monoclonal antibody or a polyclonal antibody. In addition, it can also be used in a kit as an antibody fragment which retains specific binding ability to cardiac muscle troponin, for example, Fab, Fab ′, F (ab ′) 2 or Fv.
- the antibody can be used as it is in a kit as it is, or based on the immunological method to be used, a form suitable for it, for example, a latex carrier if latex agglutination immunoassay is used.
- a high sensitivity measurement method using magnetic particles or the like is used in a fixed state, if it is a method of using a substrate such as immunochromatography in a state fixed to magnetic particles, in a state fixed to a substrate
- labeling with a labeling substance eg, enzyme, fluorescent substance, chemiluminescent substance, radioactive isotope, biotin, avidin
- a labeling substance eg, enzyme, fluorescent substance, chemiluminescent substance, radioactive isotope, biotin, avidin
- the buffer solution containing the sulfated polysaccharide may be referred to the above, and examples thereof include a sample dilution solution and an antibody solution (antibody solid phase particle solution and labeled antibody solution). Preferably, it is prepared as a specimen dilution liquid.
- the kit of the present invention can include an instruction manual describing a procedure for performing an immunological assay using the kit of the present invention, precautions for storage and handling of the kit itself, etc. .
- Reference Example 1 Preparation and Measurement of a Soluble Interleukin 2 Receptor Reagent Reference Example 1-1 Preparation of Reagent for Measurement of Soluble Interleukin 2 Receptor and Preparation of Test Sample A reagent for measurement of a soluble interleukin 2 receptor (sIL-2R) was prepared.
- sIL-2R soluble interleukin 2 receptor
- Specimen Diluent A buffer solution containing 0.1 mol / L HEPES (8.0), 0.15 mol / L NaCl, 0.05% Tween 20 was used.
- First antibody solution A magnetic particle solution in which a mouse monoclonal antibody (manufactured by R & D Systems) that recognizes sIL-2R was bound to magnetic latex particles (JSR) was used.
- JSR magnetic latex particles
- Second antibody solution A labeled antibody solution in which another mouse monoclonal antibody (manufactured by R & D Systems) that recognizes sIL-2R was labeled with alkaline phosphatase (ALP) by the maleimide method was used.
- ALP alkaline phosphatase
- Luminescent substrate solution CDP-star (manufactured by Applied Biosystems) was used.
- B / F washing solution A buffer solution containing 0.01 mol / L MOPS (7.5), 0.15 mol / L NaCl, 0.05% Triton X-100 was used.
- test sample serum obtained from a healthy person and heparinized plasma were used according to a conventional method.
- Reference Example 1-2 Measurement with a reagent for measurement of soluble interleukin 2 receptor Measurement with a fully automatic clinical examination system (STACIA: manufactured by LSI stipulatece)
- STACIA fully automatic clinical examination system
- Sample dilution solution prepared in a bottle for STACIA, first antibody solution (magnetic latex Reagents) and a second antibody solution (enzyme-labeled antibody reagent) were loaded respectively and set in the device.
- the sIL-2R in the sample reacted with the first antibody (magnetic latex) to form a magnetic latex-sIL-2R complex.
- 50 ⁇ L of a second antibody solution enzyme-labeled antibody reagent was added, and the mixture was heated at 37 ° C. for 4.4 minutes.
- a second antibody solution ALP-labeled antibody
- the ALP-labeled antibody reacted with the magnetic latex-sIL-2R complex to form a magnetic latex-sIL-2R-ALP-labeled antibody complex.
- Example 1 Influence on the reactivity of sIL-2R by the addition of a sulfated polysaccharide, polysaccharide having no sulfate group or polysaccharide having no sulfate group and compound having a sulfate group >> According to Reference Example 1 except that a sulfated polysaccharide or polysaccharide without sulfate group or polysaccharide without polysaccharide and containing a sulfate group is added to the sample dilution solution to have the following concentration in the reaction solution. went.
- Sulfated polysaccharide Dextran sulfate (molecular weight 4000) was added to the sample dilution solution to a concentration of 0.04%. Beta cyclodextrin sulfate was added to the sample dilution to be 0.04%. Sulfate-free polysaccharide: Dextran was added to the sample dilution to be 0.04%. Cyclodextrin was added to the sample dilution to be 0.04%. -Compound containing sulfate group without polysaccharides: CHAPSO was added to the sample dilution solution to be 0.04%. Sodium octanoate was added to the sample dilution to be 0.04%. Other than that, it carried out according to the reference example 1.
- polysaccharides with sulfate groups such as dextran sulfate (molecular weight 4000) and ⁇ -cyclodextrin sulfate
- the reactivity of serum and that of heparinized plasma are identical is a polysaccharide without sulfate group such as dextran or cyclodextrin, or a compound without sulfate such as CHAPSO or sodium octanoate and containing sulfate group alone.
- a polysaccharide having a sulfate group such as dextran or cyclodextrin
- a compound without sulfate such as CHAPSO or sodium octanoate and containing sulfate group alone.
- Example 2 Effect of soluble interleukin 2 receptor on the reactivity by addition of various sulfated polysaccharides to the reaction solution >> The procedure of Reference Example 1 was followed except as described below.
- Specimen Diluent A buffer solution containing 0.1 mol / L HEPES (8.0), 0.15 mol / L NaCl, 0.05% Tween 20, 0.4 mmol / L ethylenediaminetetraacetic acid was used.
- Standard product A recombinant sIL-2R diluted to 100000, 40000, 2500, 500, 0 U / mL was used.
- Each concentration (U / mL) was calculated from the luminescence count according to a known method using the standard product.
- Comparative example 1 The influence on the reactivity of sIL-2R by the addition of the polysaccharide which does not have a sulfate group and the compound which does not have polysaccharides and contains a sulfate group to the reaction liquid >> A polysaccharide having a sulfate group-containing polysaccharide and a compound having a sulfate group without a polysaccharide group, which has the same reactivity as the sulfated polysaccharide or has no sulfate group, was simultaneously added to the reaction solution and examined.
- the experiment was carried out according to Reference Example 1 except that polysaccharides having no sulfate group and polysaccharides without sulfate and containing a sulfate group were added to the sample dilution liquid to have the following concentrations.
- -Compound having sulfate group without polysaccharides: NDSB-195, NDSB-201, and NDSB-256 were added to the sample dilution liquid to be 0.385 mmol / L and 3.85 mmol / L, respectively.
- Example 3 Effect of Addition of Sulfated Polysaccharide to Reaction Solution on the Reactivity of total PSA
- Example 3-1 Preparation of reagent for measurement of total PSA and preparation of test sample A reagent for measurement of total PSA was prepared.
- Specimen Diluent A buffer solution containing 0.1 mol / L HEPES (8.0), 0.15 mol / L NaCl, 0.05% Tween 20 was used.
- First antibody solution A magnetic particle solution in which a mouse monoclonal antibody (manufactured by Biospacific) that recognizes PSA was bound to magnetic latex particles (JSR) was used.
- JSR magnetic latex particles
- Second antibody solution A labeled antibody solution in which another mouse monoclonal antibody (manufactured by Biospacific) that recognizes PSA was labeled with alkaline phosphatase (ALP) by the maleimide method was used.
- ALP alkaline phosphatase
- Luminescent substrate solution CDP-star (manufactured by Applied Biosystems) was used.
- B / F washing solution A buffer solution containing 0.01 mol / L MOPS (7.5), 0.15 mol / L NaCl, 0.05% Triton X-100 was used.
- test sample serum obtained from a healthy person and heparinized plasma were used according to a conventional method.
- Standard product A recombinant PSA diluted to 100, 50, 10, 1, 0 ng / mL was used.
- Each concentration (ng / mL) was calculated from the luminescence count according to a known method using the standard product.
- Example 3-2 Measurement and Result with Reagent for Measurement of Total PSA Measurement was carried out in the same manner as in Example 1-2 except that the measurement object was total PSA.
- the results are shown in Table 4.
- the concentration of heparinized plasma divided by the concentration of serum and then multiplied by 100 is shown as heparinized plasma / serum.
- the reactivity of total PSA was different between serum and heparinized plasma.
- the range considered to be consistent is minus 10% to plus 10%
- the reactivity of total PSA of serum and heparinized plasma is consistent by the addition of 0.002% or more of ⁇ -cyclodextrin sulfate confirmed.
- a substance to be measured for example, sIL-2R
- sIL-2R serum and heparinized plasma
- the measurement results can be obtained stably and with high accuracy.
- the clinical examination needs to be measured simply and quickly, and is measured not only in the laboratory but also in the POCT field and the like.
- the containers used for collecting the sample vary widely, and therefore, are generally used regardless of the type of sample obtained.
- the present invention is particularly useful in that it is possible to obtain stable and highly accurate measurement results when using serum and heparinized plasma. While the invention has been described in terms of specific embodiments, variations and modifications obvious to one skilled in the art are within the scope of the invention.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
しかし、安定して臨床検体を測定するために、未だ十分なものでは無かった。
本発明は、生体試料中の測定対象物質(例えば、sIL-2R)を検出する場合に、一般的に多用される、異なる血液凝固阻害剤の使用による血清、ヘパリン加血漿といった被検試料の種類に関わらず、被検試料中の干渉物質の影響を受けることなく安定的で高精度な測定値を得ることができる測定方法及びキットを提供することを目的とする。
[1]生体試料中の測定対象物質を免疫学的に測定する方法において、測定対象物質と該測定対象物質に特異的に結合する抗体との免疫複合体の形成を硫酸化多糖類の存在下で行うことを特徴とする、該測定対象物質を測定する方法、
[2]生体試料中の測定対象物質の免疫学的測定において、抗凝固剤としてヘパリンを添加した血液試料を用いた場合の測定値と、血清を用いた場合の測定値との間の乖離を減少させる方法であって、測定対象物質と該測定対象物質に特異的に結合する抗体との免疫複合体の形成を硫酸化多糖類の存在下で行うことを特徴とする、前記方法、
[3]前記硫酸化多糖類が、デキストラン硫酸、βシクロデキストリン硫酸である、[1]又は[2]の方法、
[4]前記硫酸化多糖類を検体希釈液及び/又は抗体溶液に含有する、[1]~[3]のいずれかの方法、
[5]前記形成された免疫複合体をB/F分離する工程を含む、[1]~[4]のいずれかの方法、
[6]測定対象物質に特異的に結合する第1抗体と第2抗体を接触させ、抗原抗体反応により形成された免疫複合体を測定する、[1]~[5]のいずれかの方法、
[7]測定対象物質が、可溶性インターロイキン2受容体、前立腺特異抗原である、[1]~[6]のいずれかの方法、
[8][1]~[7]のいずれかの方法のための、測定対象物質に特異的に結合する抗体と、硫酸化多糖類を含有する緩衝液を含む、該測定対象物質測定キット、
[9]前記抗体として、磁性粒子に担持された前記測定対象物質に特異的に結合する抗体を含む、[8]のキット、
[10]測定対象物質が、可溶性インターロイキン2受容体、前立腺特異抗原である、[8]又は[9]のキット。
例えば、デキストラン硫酸(分子量20,000)は0.000004%以上0.04%以下、デキストラン硫酸(分子量4,000)は0.0004%以上0.04%以下、βシクロデキストリン硫酸塩は0.02%以上0.4%以下等が挙げられる。
参考例1-1:可溶性インターロイキン2受容体測定用試薬の作製と被検試料の調製
可溶性インターロイキン2受容体(sIL-2R)の測定用の試薬を作製した。
全自動臨床検査システム(STACIA:LSIメディエンス社製)による測定
STACIA専用ボトルに、調製した検体希釈液、第1抗体溶液(磁性ラテックス試薬)、第2抗体溶液(酵素標識抗体試薬)をそれぞれ充填し、装置にセットした。以下、前記装置の運転方法に従い、測定した。
具体的には、検体 5μLに検体希釈液50μLを加え、37℃で3.5分間加温した後、第1抗体溶液(磁性ラテックス試薬)25μLを加え、37℃で4.2分間加温した。検体中のsIL-2Rは第1抗体(磁性ラテックス)と反応し、磁性ラテックス-sIL-2R複合体を形成した。次いで、第2抗体溶液(酵素標識抗体試薬)50μLを加え、37℃で4.4分間加温した。第2抗体溶液(ALP標識抗体)を加えると、ALP標識抗体は磁性ラテックス-sIL-2R複合体と反応し、磁性ラテックス-sIL-2R-ALP標識抗体複合体を形成した。洗浄によって未反応の抗体およびsIL-2Rを除去(B/F分離)した後、発光基質液100μLを加え、37℃で 2.7分間反応後に発光量を測定した。CDP-Starを加えると、CDP-Starは複合体中のALPにより加水分解され発光する。検出は、光電子増倍管(PMT)により検出される化学発光基質の発光カウントを測定結果とした。
硫酸化多糖類又は硫酸基を持たない多糖類又は多糖類を持たず硫酸基を含む化合物を、反応液中に下記の濃度になるように検体希釈液に添加したこと以外は、参考例1に従って行った。
・硫酸化多糖類:デキストラン硫酸塩(分子量4000)を、0.04%になるように検体希釈液に添加した。βシクロデキストリン硫酸塩を、0.04%になるように検体希釈液に添加した。
・硫酸基を持たない多糖類:デキストランを、0.04%になるように検体希釈液に添加した。シクロデキストリンを、0.04%になるように検体希釈液に添加した。
・多糖類を持たず硫酸基を含む化合物:CHAPSOを、0.04%になるように検体希釈液に添加した。オクタン酸ナトリウムを、0.04%になるように検体希釈液に添加した。それ以外は、参考例1に従って行った。
以下に記載すること以外は、参考例1の手法に従って行った。
・検体希釈液:0.1mol/L HEPES(8.0)、0.15mol/L NaCl、0.05% Tween20、0.4mmol/L エチレンジアミン四酢酸を含む緩衝液を使用した。
・デキストラン硫酸(分子量20,000)を、反応液中に各濃度(0.0000004、0.000004、0.00004、0.0004、0.004、0.04%)になるように検体希釈液に添加した。
・デキストラン硫酸(分子量4,000)を、反応液中に各濃度(0.000004、0.00004、0.0004、0.004、0.04%)になるように検体希釈液に添加した。
・βシクロデキストリン硫酸塩を、反応液中に各濃度(0.004、0.01、0.02、0.04、0.08、0.2、0.4%)になるように検体希釈液に添加した。
・標準品:組み換えsIL-2Rを100000、40000、2500、500、0U/mLになるように希釈したものを用いた。希釈には0.05mol/L PBS(7.4)、0.05% Tween20、0.1% BSA、0.05% アジ化ナトリウムを含む緩衝液を使用した。該標準品を使用し、公知の方法に従って、発光カウントから各濃度(U/mL)を算出した。
その結果、一致とみなす範囲をマイナス10%~プラス10%とすると、デキストラン硫酸塩(分子量20,000)は0.000004%以上、デキストラン硫酸(分子量4,000)は0.0004%以上、βシクロデキストリン硫酸塩は0.004%以上添加されることにより、血清およびヘパリン加血漿の可溶性インターロイキン2受容体の反応性が一致することが確認された。
硫酸化多糖類と同様な反応性となるか、硫酸基を持たない多糖類及び多糖類を持たず硫酸基を含む化合物を、同時に反応液中添加して検討した。硫酸基を持たない多糖類及び多糖類を持たず硫酸基を含む化合物を、下記の濃度になるように検体希釈液に添加したこと以外は、参考例1に従って行った。
・多糖類を持たず硫酸基を含む化合物:NDSB-195、NDSB-201、NDSB-256を、それぞれ0.385mmol/L、3.85mmol/Lになるように検体希釈液に添加した。
・多糖類を持たず硫酸基を含む化合物及び硫酸基を持たない多糖類の混合:NDSB-195を3.85mmol/L、及び、デキストラン(分子量2000)を0.19%になるように検体希釈液に添加した。
硫酸基を持たない多糖類及び多糖類を持たず硫酸基を含む化合物を共存させた場合では、実施例1、2の硫酸基を持つ多糖類のような効果は得られず、硫酸基を持つ多糖類を共存させた場合でないとこの高い効果が得られないことは、硫酸基と多糖類の存在によるものではないことから、意外な結果であった。
実施例3-1:total PSA測定用試薬の作製と被検試料の調製
total PSAの測定用の試薬を作製した。
測定対象をtotal PSAとしたこと以外は、参考例1-2と同様に実施した。
その結果を表4に示す。ヘパリン加血漿の濃度を血清の濃度で割った後100を掛けたものを、ヘパリン加血漿/血清として示した。添加無しの例だと、血清およびヘパリン加血漿とでは、total PSAの反応性が異なることがわかった。さらに、一致とみなす範囲をマイナス10%~プラス10%とすると、βシクロデキストリン硫酸塩は0.002%以上添加されることにより、血清およびヘパリン加血漿のtotal PSAの反応性が一致することが確認された。
以上、本発明を特定の態様に沿って説明したが、当業者に自明の変法や改良は本発明の範囲に含まれる。
Claims (10)
- 生体試料中の測定対象物質を免疫学的に測定する方法において、測定対象物質と該測定対象物質に特異的に結合する抗体との免疫複合体の形成を硫酸化多糖類の存在下で行うことを特徴とする、該測定対象物質を測定する方法。
- 生体試料中の測定対象物質の免疫学的測定において、抗凝固剤としてヘパリンを添加した血液試料を用いた場合の測定値と、血清を用いた場合の測定値との間の乖離を減少させる方法であって、測定対象物質と該測定対象物質に特異的に結合する抗体との免疫複合体の形成を硫酸化多糖類の存在下で行うことを特徴とする、前記方法。
- 前記硫酸化多糖類が、デキストラン硫酸、βシクロデキストリン硫酸である、請求項1又は2に記載の方法。
- 前記硫酸化多糖類を検体希釈液及び/又は抗体溶液に含有する、請求項1~3のいずれか一項に記載の方法。
- 前記形成された免疫複合体をB/F分離する工程を含む、請求項1~4のいずれか一項に記載の方法。
- 測定対象物質に特異的に結合する第1抗体と第2抗体を接触させ、抗原抗体反応により形成された免疫複合体を測定する、請求項1~5のいずれか一項に記載の方法。
- 測定対象物質が、可溶性インターロイキン2受容体、前立腺特異抗原である、請求項1~6のいずれか一項に記載の方法。
- 請求項1~7のいずれか一項に記載の方法のための、測定対象物質に特異的に結合する抗体と、硫酸化多糖類を含有する緩衝液を含む、該測定対象物質測定キット。
- 前記抗体として、磁性粒子に担持された前記測定対象物質に特異的に結合する抗体を含む、請求項8に記載のキット。
- 測定対象物質が、可溶性インターロイキン2受容体、前立腺特異抗原である、請求項8又は9に記載のキット。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020187032752A KR102228440B1 (ko) | 2016-04-13 | 2017-04-12 | 황산화 다당류를 이용한 면역학적 측정법 |
US16/092,684 US11422128B2 (en) | 2016-04-13 | 2017-04-12 | Immunoassay employing sulfated polysaccharide |
EP17782424.0A EP3444612B1 (en) | 2016-04-13 | 2017-04-12 | Immunoassay employing sulfated polysaccharide |
JP2018512041A JP6668459B2 (ja) | 2016-04-13 | 2017-04-12 | 硫酸化多糖類を用いた免疫学的測定法 |
ES17782424T ES2910089T3 (es) | 2016-04-13 | 2017-04-12 | Inmunoensayo que emplea polisacárido sulfatado |
CN201780023301.8A CN109073641B (zh) | 2016-04-13 | 2017-04-12 | 使用硫酸化多糖类的免疫学测定法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016-080660 | 2016-04-13 | ||
JP2016080660 | 2016-04-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017179611A1 true WO2017179611A1 (ja) | 2017-10-19 |
Family
ID=60042142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/014943 WO2017179611A1 (ja) | 2016-04-13 | 2017-04-12 | 硫酸化多糖類を用いた免疫学的測定法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US11422128B2 (ja) |
EP (1) | EP3444612B1 (ja) |
JP (1) | JP6668459B2 (ja) |
KR (1) | KR102228440B1 (ja) |
CN (1) | CN109073641B (ja) |
ES (1) | ES2910089T3 (ja) |
WO (1) | WO2017179611A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021200940A1 (ja) | 2020-03-31 | 2021-10-07 | 富士レビオ株式会社 | 血中アミロイドβの免疫測定方法及びそのためのキット |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110095615A (zh) * | 2019-05-27 | 2019-08-06 | 山东艾科达生物科技有限公司 | 一种测定超敏c反应蛋白含量的试剂盒 |
CN113588943A (zh) * | 2020-11-04 | 2021-11-02 | 北京北方生物技术研究所有限公司 | 一种天然聚合多糖用于制备样本处理液及其在免疫层析检测试剂盒的应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4829009A (en) * | 1986-02-21 | 1989-05-09 | The Regents Of The University Of California | Noise controlled immunoassays |
JP2002502979A (ja) * | 1998-02-05 | 2002-01-29 | ビオ−ラド・パストゥール | ヘパリンによる干渉なしのトロポニンアッセイ |
JP2009053195A (ja) * | 2007-08-28 | 2009-03-12 | Ortho Clinical Diagnostics Inc | イムノアッセイにおける非特異結合を低減するためのグリコサミノグリカンの使用 |
US20120045847A1 (en) * | 2010-08-20 | 2012-02-23 | Siemens Healthcare Diagnostics Inc. | Assay for analytes using multiple receptors |
WO2012115221A1 (ja) * | 2011-02-25 | 2012-08-30 | 三菱化学メディエンス株式会社 | 心筋トロポニンの測定法 |
JP2013152247A (ja) * | 2013-04-12 | 2013-08-08 | Abbott Japan Co Ltd | 非特異的相互作用抑制剤及びその診断測定系への応用 |
WO2017078119A1 (ja) * | 2015-11-05 | 2017-05-11 | 富士レビオ株式会社 | 心筋トロポニンi測定試薬及び方法 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57182169A (en) * | 1981-05-02 | 1982-11-09 | Mitsubishi Chem Ind Ltd | Measuring method for antigen-antibody reaction |
US4707443A (en) | 1985-04-19 | 1987-11-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Soluble interleukin-2 receptor as a disease indicator and a method of assaying the same |
US5189067A (en) | 1991-04-11 | 1993-02-23 | Dow Corning Corporation | Skin treatment with siliconates |
WO1992021769A1 (en) * | 1991-05-30 | 1992-12-10 | Abbott Laboratories | Reagents containing a nonspecific binding blocker in ion-capture binding assays |
JPH05189067A (ja) | 1992-01-09 | 1993-07-30 | Nissin Electric Co Ltd | 電圧変動抑制装置の制御方式 |
US5466580A (en) * | 1993-09-22 | 1995-11-14 | Xoma Corporation | Method for quantifying BPI in body fluids |
JPH08226920A (ja) | 1995-02-20 | 1996-09-03 | Masashi Funayama | グリコヘモグロビンおよびフルクトサミンの定量方法 |
US6656508B2 (en) | 1997-04-17 | 2003-12-02 | Amgen Inc. | Sustained-release alginate gels |
CA2422856C (en) * | 2000-09-25 | 2012-02-07 | Abbott Laboratories | Methods and kits for decreasing interferences of assay samples containing plasma or serum in specific binding assays by using a large polycation |
WO2002063302A1 (en) * | 2001-02-07 | 2002-08-15 | Immunomatrix Inc. | A method for reducing heparin interference in diagnostic tests for cardiac troponin |
NZ535276A (en) | 2002-02-28 | 2008-04-30 | Microsens Biophage Ltd | Binding of pathological forms of prion proteins |
WO2004092733A1 (en) | 2003-04-14 | 2004-10-28 | Caliper Life Sciences, Inc. | Reduction of migration shift assay interference |
CN1969189B (zh) | 2004-06-14 | 2012-03-21 | 协和梅迪克斯株式会社 | 非特异性反应被抑制的可溶性白介素-2受体免疫学测定方法和试剂 |
JP2007170992A (ja) | 2005-12-22 | 2007-07-05 | Abbott Japan Co Ltd | ホモシステインの免疫学的測定方法 |
EP3062104A1 (en) * | 2008-07-04 | 2016-08-31 | Sekisui Medical Co., Ltd. | Method for enhancing sensitivity or method for avoiding influence of hemoglobin in immunological measurement |
JP5395076B2 (ja) | 2008-07-22 | 2014-01-22 | アークレイ株式会社 | キャピラリー電気泳動法による分析装置および分析方法 |
JP2010107363A (ja) | 2008-10-30 | 2010-05-13 | Sysmex Corp | トロポニンiの測定方法及び測定用試薬キット |
JP2010127827A (ja) | 2008-11-28 | 2010-06-10 | Abbott Japan Co Ltd | 非特異的相互作用抑制剤及びその診断測定系への応用 |
JP5674339B2 (ja) | 2009-05-22 | 2015-02-25 | 協和メデックス株式会社 | 可溶性インターロイキン−2受容体の測定方法及び測定用試薬 |
JP6157464B2 (ja) | 2011-07-19 | 2017-07-05 | バクスアルタ ゲーエムベーハー | 非抗凝固性硫酸化多糖の経口製剤を改善するための添加剤としての吸収促進剤 |
JP6116268B2 (ja) * | 2013-01-31 | 2017-04-19 | デンカ生研株式会社 | 生体粘膜由来検体測定イムノアッセイにおいて偽陰性を抑制する方法 |
US20140273021A1 (en) * | 2013-03-14 | 2014-09-18 | Enzo Biochem, Inc. | Vitamin d assays |
-
2017
- 2017-04-12 ES ES17782424T patent/ES2910089T3/es active Active
- 2017-04-12 WO PCT/JP2017/014943 patent/WO2017179611A1/ja active Application Filing
- 2017-04-12 JP JP2018512041A patent/JP6668459B2/ja active Active
- 2017-04-12 KR KR1020187032752A patent/KR102228440B1/ko active IP Right Grant
- 2017-04-12 EP EP17782424.0A patent/EP3444612B1/en active Active
- 2017-04-12 US US16/092,684 patent/US11422128B2/en active Active
- 2017-04-12 CN CN201780023301.8A patent/CN109073641B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4829009A (en) * | 1986-02-21 | 1989-05-09 | The Regents Of The University Of California | Noise controlled immunoassays |
JP2002502979A (ja) * | 1998-02-05 | 2002-01-29 | ビオ−ラド・パストゥール | ヘパリンによる干渉なしのトロポニンアッセイ |
JP2009053195A (ja) * | 2007-08-28 | 2009-03-12 | Ortho Clinical Diagnostics Inc | イムノアッセイにおける非特異結合を低減するためのグリコサミノグリカンの使用 |
US20120045847A1 (en) * | 2010-08-20 | 2012-02-23 | Siemens Healthcare Diagnostics Inc. | Assay for analytes using multiple receptors |
WO2012115221A1 (ja) * | 2011-02-25 | 2012-08-30 | 三菱化学メディエンス株式会社 | 心筋トロポニンの測定法 |
JP2013152247A (ja) * | 2013-04-12 | 2013-08-08 | Abbott Japan Co Ltd | 非特異的相互作用抑制剤及びその診断測定系への応用 |
WO2017078119A1 (ja) * | 2015-11-05 | 2017-05-11 | 富士レビオ株式会社 | 心筋トロポニンi測定試薬及び方法 |
Non-Patent Citations (7)
Title |
---|
ANONYMOUS, SERUFURI N IL -2R, 2010, JP, pages 1 - 6, XP009516336, Retrieved from the Internet <URL:http://www.info.pmda.go.jp/downfiles/ivd/PDF/230187_22000AMX02422000_A_01_03.pdf> * |
ANONYMOUS: "DETAMINA CL IL -2R", DETAMINA CL IL -2R, 2011, pages 1 - 6, XP009516377 * |
COLLINSON P O: "Rapid troponin T measurement in whole blood for detection of myocardial damage", ANN CLIN BIOCHEM, vol. 32, no. 5, 1995, pages 454 - 458, XP002086285 * |
DE JONGH R: "The Effects of Anticoagulation and Processing on Assays of IL -6, sIL-6R, sIL-2R and Soluble Transferrin Receptor", CYTOKINE, vol. 9, no. 9, 1 September 1997 (1997-09-01), pages 696 - 701, XP055580009, DOI: 10.1006/cyto.1997.0217 * |
RYO TAKANO: "Sulfation and Desulfation of Polysaccharides: Effects of the Modification on their Properties", KAGAKU TO SEIBUTSU, vol. 34, no. 9, 1 January 1996 (1996-01-01), pages 598 - 604, XP055580020, DOI: 10.1271/kagakutoseibutsu1962.34.598 * |
See also references of EP3444612A4 * |
SIEMENS HEALTHCARE DIAGNOSTICS KABUSHIKI KAISHA: "Siemens Immulyze IL -2R II", PHARMACEUTICALS AND MEDICAL DEVICES AGENCY, 2015, pages 1 - 2, XP009516337 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021200940A1 (ja) | 2020-03-31 | 2021-10-07 | 富士レビオ株式会社 | 血中アミロイドβの免疫測定方法及びそのためのキット |
Also Published As
Publication number | Publication date |
---|---|
JPWO2017179611A1 (ja) | 2019-02-21 |
US20190145965A1 (en) | 2019-05-16 |
EP3444612B1 (en) | 2022-03-23 |
ES2910089T3 (es) | 2022-05-11 |
CN109073641A (zh) | 2018-12-21 |
EP3444612A4 (en) | 2019-12-11 |
CN109073641B (zh) | 2022-03-11 |
EP3444612A1 (en) | 2019-02-20 |
KR20180128972A (ko) | 2018-12-04 |
US11422128B2 (en) | 2022-08-23 |
JP6668459B2 (ja) | 2020-03-18 |
KR102228440B1 (ko) | 2021-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5864530B2 (ja) | 心筋トロポニンの測定法 | |
JP2009085753A (ja) | サンドイッチイムノアッセイ法 | |
JP6668459B2 (ja) | 硫酸化多糖類を用いた免疫学的測定法 | |
US20220137036A1 (en) | Controls for implementing multiplex analysis methods | |
JPWO2018047793A1 (ja) | 腫瘍マーカーの測定方法及び測定試薬 | |
JP4167491B2 (ja) | 全血測定法 | |
KR102390761B1 (ko) | HBsAg의 정량적 검출을 위한 키트 및 방법 | |
WO2009084369A1 (ja) | Hiv-1抗原の検出用試薬及び検出方法 | |
JP4418895B2 (ja) | 非特異的反応抑制剤、非特異的反応の抑制方法、免疫学的測定方法及び免疫学的測定試薬 | |
JP2014228385A (ja) | 免疫試験方法および免疫試験キット | |
JP6697314B2 (ja) | 可溶性インターロイキン2受容体の免疫学的測定法 | |
US20220170932A1 (en) | Novel immunoassay format for measuring total antibodies | |
JP2001033453A (ja) | リガンドの測定方法 | |
JP2021099243A (ja) | 免疫学的測定法 | |
JP7268306B2 (ja) | 生体試料中の測定対象物質を免疫学的に測定する方法 | |
JPH08292192A (ja) | 免疫測定法 | |
JP2004117068A (ja) | 免疫測定試薬および免疫測定方法 | |
CN117098998A (zh) | 高灵敏度免疫学测定试剂及测定方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2018512041 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20187032752 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017782424 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017782424 Country of ref document: EP Effective date: 20181113 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17782424 Country of ref document: EP Kind code of ref document: A1 |